AlzeCure Pharma AB stock analysis
AlzeCure Pharma AB (AC6) Stock Price & Analysis
AC6 Stock Chart & Stats
- Day’s Range
- EUR 0.54 - EUR 0.55
- 52-Week Range
- EUR 0.07 - EUR 0.74
- Previous Close
- EUR 0.56
- Volume
- N/A
- Average Volume (3M)
- 57
- Market Cap
- EUR 79.47M
- Enterprise Value
- EUR 849.11M
- Total Cash (Recent Filing)
- EUR 231.93M
- Total Debt (Recent Filing)
- EUR 1.72M
- Price to Earnings (P/E)
- 10.7
- Beta
- -0.37
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
The company has comparatively low financial leverage, which limits interest and refinancing pressure relative to its equity base. This provides more balance-sheet flexibility than a highly indebted biotech and can help preserve strategic options while pipeline programs progress.
Proprietary CNS Pipeline
A proprietary small-molecule pipeline gives AlzeCure control over internally generated drug candidates and potential intellectual-property value. Concentration on major CNS conditions such as Alzheimer’s disease and pain also targets areas with substantial unmet medical needs.
Partnering-based Monetization
The partnering model offers a path to monetize research without requiring AlzeCure to fund every development and commercialization stage alone. Successful deals could provide upfront and milestone payments, while royalties may create longer-term income from partnered products.
Bears Say
No Commercial Revenue
Zero reported revenue means the company has not yet established a commercial income stream to offset research and development spending. Until a candidate is partnered successfully or reaches approval, financial performance remains dependent on funding rather than recurring product sales.
Persistent Operating Losses
Large and persistent losses show that current operating costs materially exceed any income generated by the business. Worsening losses in the latest periods could accelerate depletion of financial resources and increase the capital required to advance the pipeline.
Heavy Cash Burn And Funding Need
Substantial negative operating and free cash flow indicates that the company is consuming cash to sustain development rather than generating internal funding. Continued burn increases dependence on future financing or partnerships and may constrain the pace and scope of pipeline investment.
AC6 FAQ
What was AlzeCure Pharma AB’s price range in the past 12 months?
What is AlzeCure Pharma AB’s market cap?
When is AlzeCure Pharma AB’s upcoming earnings report date?
How were AlzeCure Pharma AB’s earnings last quarter?
Is AlzeCure Pharma AB overvalued?
Does AlzeCure Pharma AB pay dividends?
What is AlzeCure Pharma AB’s EPS estimate?
How many shares outstanding does AlzeCure Pharma AB have?
What happened to AlzeCure Pharma AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of AlzeCure Pharma AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
AlzeCure Pharma AB
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Johan Sandin
- Employees
- 10
- Website
- www.alzecurepharma.se
- Address
- Hälsovägen 7, Huddinge, AB, 141 57, SE
AlzeCure Pharma AB (AC6) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 5 | 10 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 4 | 0 | 8 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| SE:CAMXCamurus AB | ||
| SE:ALZAlzinova AB | ||
| SE:BIOA.BBioArctic AB Class B | ||
| SE:SANIONSaniona AB | ||
| SE:IRLAB.AIRLAB Therapeutics AB Class A |

